7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Ferrari SL et al. | Bone response to intermittent parathyroid hormone is altered in mice null for {beta}-Arrestin2. | 2005 | Endocrinology | pmid:15705780 |
Heymann D et al. | Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools. | 2005 | Drug Discov. Today | pmid:15708742 |
Mezquita-Raya P et al. | The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. | 2005 | Osteoporos Int | pmid:15711777 |
Pantouli E et al. | Inflammatory cytokines activate p38 MAPK to induce osteoprotegerin synthesis by MG-63 cells. | 2005 | Biochem. Biophys. Res. Commun. | pmid:15721297 |
Korcok J et al. | P2Y6 nucleotide receptors activate NF-kappaB and increase survival of osteoclasts. | 2005 | J. Biol. Chem. | pmid:15722352 |
Bock O et al. | Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders. | 2005 | J. Pathol. | pmid:15726648 |
Mosheimer BA et al. | Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. | 2005 | J. Clin. Endocrinol. Metab. | pmid:15728209 |
Han KO et al. | The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone. | 2005 | Clin. Endocrinol. (Oxf) | pmid:15730418 |
Xiao XH et al. | [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro]. | 2004 | Zhonghua Yi Xue Za Zhi | pmid:15730627 |
Tiranathanagul S et al. | Actinobacillus actinomycetemcomitans lipopolysaccharide activates matrix metalloproteinase-2 and increases receptor activator of nuclear factor-kappaB ligand expression in human periodontal ligament cells. | 2004 | J. Periodontol. | pmid:15732867 |
Schneider HG and Sentry J | Multiple myeloma. | 2005 | N. Engl. J. Med. | pmid:15736296 |
Ambroszkiewicz J et al. | [Biochemical bone resorption markers in children with osteosarcoma]. | 2004 Apr-Jun | Med Wieku Rozwoj | pmid:15738598 |
Skládal P et al. | Investigation of osteoprotegerin interactions with ligands and antibodies using piezoelectric biosensors. | 2005 | Biosens Bioelectron | pmid:15741072 |
Kanno T et al. | Platelet-rich plasma enhances human osteoblast-like cell proliferation and differentiation. | 2005 | J. Oral Maxillofac. Surg. | pmid:15742288 |
Mazziotti G et al. | Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. | 2005 | J. Bone Miner. Res. | pmid:15746993 |
Corey E et al. | Osteoprotegerin in prostate cancer bone metastasis. | 2005 | Cancer Res. | pmid:15753366 |
Moschen AR et al. | The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. | 2005 | Gut | pmid:15753532 |
Nagasaki T et al. | Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function. | 2005 | Eur. J. Endocrinol. | pmid:15757850 |
Kostenuik PJ | Revisiting the seed and soil theory of bone metastasis: new tools, same answer. | 2004 | J Musculoskelet Neuronal Interact | pmid:15758267 |
Simmons CA et al. | Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. | 2005 | Circ. Res. | pmid:15761200 |
Gallant MA et al. | Production of prostaglandin D(2) by human osteoblasts and modulation of osteoprotegerin, RANKL, and cellular migration by DP and CRTH2 receptors. | 2005 | J. Bone Miner. Res. | pmid:15765187 |
Mandelin J et al. | Pseudosynovial fluid from loosened total hip prosthesis induces osteoclast formation. | 2005 | J. Biomed. Mater. Res. Part B Appl. Biomater. | pmid:15768436 |
Crisafulli A et al. | Effects of the phytoestrogen genistein on cardiovascular risk factors in postmenopausal women. | 2005 | Menopause | pmid:15772566 |
Mizuno N et al. | Characterization of epithelial cells derived from periodontal ligament by gene expression patterns of bone-related and enamel proteins. | 2005 | Cell Biol. Int. | pmid:15774307 |
Indridason OS et al. | Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. | 2005 | Osteoporos Int | pmid:15776220 |
Voskaridou E and Terpos E | Osteoprotegerin to soluble receptor activator of nuclear factor kappa-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3. | 2005 | Eur. J. Haematol. | pmid:15777350 |
Mossetti G et al. | Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment. | 2005 | Bone | pmid:15777635 |
Janssens K et al. | An intermediate form of juvenile Paget's disease caused by a truncating TNFRSF11B mutation. | 2005 | Bone | pmid:15777670 |
Fábrega E et al. | Osteoprotegerin and RANKL in alcoholic liver cirrhosis. | 2005 | Liver Int. | pmid:15780054 |
Fukushima H et al. | IL-1-induced receptor activator of NF-kappa B ligand in human periodontal ligament cells involves ERK-dependent PGE2 production. | 2005 | Bone | pmid:15780952 |
Regmi A et al. | Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation. | 2005 | Bone | pmid:15780954 |
Abrahamsen B et al. | Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. | 2005 | Bone | pmid:15781001 |
Zhao HY et al. | The influence of Lys3Asn polymorphism in the osteoprotegerin gene on bone mineral density in Chinese postmenopausal women. | 2005 | Osteoporos Int | pmid:15782282 |
Bezerra MC et al. | RANK, RANKL and osteoprotegerin in arthritic bone loss. | 2005 | Braz. J. Med. Biol. Res. | pmid:15785827 |
Stilgren LS et al. | [The cytokine system of bone tissue]. | 2005 | Ugeskr. Laeg. | pmid:15789838 |
Fukushima H et al. | Parathyroid-hormone-related protein induces expression of receptor activator of NF-{kappa}B ligand in human periodontal ligament cells via a cAMP/protein kinase A-independent pathway. | 2005 | J. Dent. Res. | pmid:15790738 |
Konduri K et al. | Immunoglobulin M myeloma: evaluation of molecular features and cytokine expression. | 2005 | Clin Lymphoma | pmid:15794867 |
Bord S et al. | Megakaryocytes modulate osteoblast synthesis of type-l collagen, osteoprotegerin, and RANKL. | 2005 | Bone | pmid:15794927 |
Giuliani N et al. | Update on the pathogenesis of osteolysis in multiple myeloma patients. | 2004 | Acta Biomed | pmid:15796087 |
Contractor T et al. | Osteoclasts resorb protein-free mineral (Osteologic discs) efficiently in the absence of osteopontin. | 2005 Mar-Apr | In Vivo | pmid:15796195 |
Zannettino AC et al. | Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. | 2005 | J. Cell. Physiol. | pmid:15799029 |
Tada T et al. | Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts. | 2005 | Int. J. Cancer | pmid:15800904 |
Mandelin J et al. | Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K. | 2005 | J. Rheumatol. | pmid:15801030 |
Holmen SL et al. | Essential role of beta-catenin in postnatal bone acquisition. | 2005 | J. Biol. Chem. | pmid:15802266 |
Bernstein CN et al. | Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study. | 2005 | Inflamm. Bowel Dis. | pmid:15803021 |
Mitani M et al. | Estrogen specifically stimulates expression and production of osteoprotegerin from rheumatoid synovial fibroblasts. | 2005 | Int. J. Mol. Med. | pmid:15806305 |
Ling LJ et al. | Areca nut extracts modulated expression of alkaline phosphatase and receptor activator of nuclear factor kappaB ligand in osteoblasts. | 2005 | J. Clin. Periodontol. | pmid:15811051 |
Maïmoun L et al. | Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury. | 2005 | Calcif. Tissue Int. | pmid:15812577 |
Ulrich-Vinther M and Andreassen TT | Osteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strength. | 2005 | Calcif. Tissue Int. | pmid:15812581 |
Ishizuka K et al. | Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol. | 2005 | Neurosci. Lett. | pmid:15814197 |
Cui N et al. | Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice. | 2005 | Clin. Cancer Res. | pmid:15814653 |
Gorczynski RM et al. | Neutral buoyancy and sleep-deprived serum factors alter expression of cytokines regulating osteogenesis. | 2005 May-Jun | Acta Astronaut | pmid:15835039 |
Essalihi R et al. | Phenotypic modulation of vascular smooth muscle cells during medial arterial calcification: a role for endothelin? | 2004 | J. Cardiovasc. Pharmacol. | pmid:15838266 |
Morony S et al. | The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. | 2005 | Endocrinology | pmid:15845617 |
Rhee EJ et al. | The effects of C161-->T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-gamma gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women. | 2005 | Am. J. Obstet. Gynecol. | pmid:15846185 |
Mahamed DA et al. | G(-) anaerobes-reactive CD4+ T-cells trigger RANKL-mediated enhanced alveolar bone loss in diabetic NOD mice. | 2005 | Diabetes | pmid:15855336 |
Leder BZ and Finkelstein JS | Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. | 2005 | Osteoporos Int | pmid:15856361 |
Galli C et al. | Comparison of human mandibular osteoblasts grown on two commercially available titanium implant surfaces. | 2005 | J. Periodontol. | pmid:15857069 |
Suzuki K et al. | Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density. | 2005 | Diabetes Res. Clin. Pract. | pmid:15860239 |
Glass DA et al. | Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. | 2005 | Dev. Cell | pmid:15866165 |
Valenta A et al. | Combined treatment with PTH (1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats. | 2005 | Bone | pmid:15869920 |
Chan MH et al. | Specific biochemical markers of bone metabolism and cytokine study confirm the diagnosis of malignant infantile osteopetrosis at birth using cord blood sample. | 2005 | Pathology | pmid:15875734 |
Seminari E et al. | Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. | 2005 | HIV Med. | pmid:15876279 |
Schett G et al. | Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. | 2005 | Arthritis Rheum. | pmid:15880601 |
Moe SM et al. | Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). | 2005 | Kidney Int. | pmid:15882271 |
Ueland T et al. | Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. | 2005 | Circulation | pmid:15883214 |
Sabokbar A et al. | Arthroplasty membrane-derived fibroblasts directly induce osteoclast formation and osteolysis in aseptic loosening. | 2005 | J. Orthop. Res. | pmid:15885469 |
Skoumal M et al. | Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. | 2005 | Rheumatol. Int. | pmid:15889303 |
Inoue H et al. | Prostate cancer mediates osteoclastogenesis through two different pathways. | 2005 | Cancer Lett. | pmid:15890244 |
Lynch CC et al. | MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. | 2005 | Cancer Cell | pmid:15894268 |
Choi BK et al. | Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola, and Treponema socranskii. | 2005 | J. Periodontol. | pmid:15898943 |
Carda C et al. | Osteoprotegerin (OPG) and RANKL expression and distribution in developing human craniomandibular joint. | 2005 | Tissue Cell | pmid:15899507 |
Chang K et al. | Pulsed electromagnetic fields stimulation affects osteoclast formation by modulation of osteoprotegerin, RANK ligand and macrophage colony-stimulating factor. | 2005 | J. Orthop. Res. | pmid:15913941 |
Depil S et al. | Evaluation and prognostic value of serum osteoprotegerin in multiple myeloma. | 2005 | Br. J. Haematol. | pmid:15916694 |
Rasmussen LM and Ledet T | Osteoprotegerin and diabetic macroangiopathy. | 2005 | Horm. Metab. Res. | pmid:15918117 |
Tanabe N et al. | IL-1 alpha stimulates the formation of osteoclast-like cells by increasing M-CSF and PGE2 production and decreasing OPG production by osteoblasts. | 2005 | Life Sci. | pmid:15921993 |
Crisafulli A et al. | Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. | 2005 | Clin. Sci. | pmid:15926884 |
Koh JM et al. | Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells. | 2005 | J. Endocrinol. | pmid:15930166 |
Bhattacharya A et al. | Inhibition of osteoporosis in autoimmune disease prone MRL/Mpj-Fas(lpr) mice by N-3 fatty acids. | 2005 | J Am Coll Nutr | pmid:15930486 |
Buemi M et al. | Osteoprotegerin, IL-6, IL-1, TNF-alpha and TGF-beta concentrations during acetate-free biofiltration. | 2005 Mar-Apr | J. Nephrol. | pmid:15931642 |
Kerschan-Schindl K et al. | Serum levels of cathepsin K decrease with age in both women and men. | 2005 | Exp. Gerontol. | pmid:15935595 |
Ugur-Altun B et al. | The relationship between insulin resistance assessed by HOMA-IR and serum osteoprotegerin levels in obesity. | 2005 | Diabetes Res. Clin. Pract. | pmid:15936463 |
Moran CS et al. | Association of osteoprotegerin with human abdominal aortic aneurysm progression. | 2005 | Circulation | pmid:15939823 |
Li F et al. | Annexin II stimulates RANKL expression through MAPK. | 2005 | J. Bone Miner. Res. | pmid:15940368 |
Sen O et al. | The relation between serum levels of osteoprotegerin and postoperative epidural fibrosis in patients who underwent surgery for lumbar disc herniation. | 2005 | Neurol. Res. | pmid:15949247 |
Saunders MM et al. | Mechanical stimulation effects on functional end effectors in osteoblastic MG-63 cells. | 2006 | J Biomech | pmid:15953606 |
Liu JZ et al. | [Construction and biological activity study of human osteoprotegerin expressing adenoviral system]. | 2003 | Sheng Wu Gong Cheng Xue Bao | pmid:15969033 |
Liu JZ et al. | [The OPG/RANKL/RANK system and bone resorptive disease]. | 2003 | Sheng Wu Gong Cheng Xue Bao | pmid:15971575 |
Frick KK et al. | RANK ligand and TNF-alpha mediate acid-induced bone calcium efflux in vitro. | 2005 | Am. J. Physiol. Renal Physiol. | pmid:15972386 |
Lossdörfer S et al. | PTH(1-34) affects osteoprotegerin production in human PDL cells in vitro. | 2005 | J. Dent. Res. | pmid:15972592 |
Arko B et al. | Association of the osteoprotegerin gene polymorphisms with bone mineral density in postmenopausal women. | 2005 | Maturitas | pmid:15978970 |
Bock O et al. | Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression of osteoprotegerin. | 2005 | Br. J. Haematol. | pmid:15982347 |
Fiore CE et al. | Hepatitis C-associated osteosclerosis (HCAO): report of a new case with involvement of the OPG/RANKL system. | 2005 | Osteoporos Int | pmid:15983730 |
Amizuka N et al. | Histological evaluation for "bone quality" on two mouse models with different bone remodeling. | 2005 | J. Bone Miner. Metab. | pmid:15984413 |
Ziegler S et al. | Endurance running acutely raises plasma osteoprotegerin and lowers plasma receptor activator of nuclear factor kappa B ligand. | 2005 | Metab. Clin. Exp. | pmid:15988704 |
Yamada N et al. | Down-regulation of osteoprotegerin production in bone marrow macrophages by macrophage colony-stimulating factor. | 2005 | Cytokine | pmid:15996478 |
Quinn JE et al. | Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. | 2005 | Prostate Cancer Prostatic Dis. | pmid:15999121 |
Mangashetti LS et al. | IL-4 inhibits bone-resorbing activity of mature osteoclasts by affecting NF-kappa B and Ca2+ signaling. | 2005 | J. Immunol. | pmid:16002690 |
Whang PG et al. | The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. | 2005 | J. Orthop. Res. | pmid:16005175 |
Bashir A et al. | Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene. | 2005 | Steroids | pmid:16005483 |